A recent study published in The Lancet Oncology suggests that cabozantinib may offer promising efficacy for patients with advanced adrenocortical carcinoma. The research, led by Matthew T. Campbell, M.D., from The University of Texas MD Anderson Cancer Center, conducted a phase 2 trial on adults with this condition who were not eligible for surgery with a curative intent.
The study, which included 18 patients enrolled between 2018 and 2021, found that 72.2 percent of patients had progression-free survival at four months, with a median progression-free survival of six months. The most common grade 3 adverse events reported were lipase elevation, elevated γ-glutamyl transferase concentrations, elevated alanine aminotransferase concentrations, hypophosphatemia, and hypertension. However, there were no treatment-related deaths reported.
The authors of the study noted that cabozantinib showed promising activity and had a manageable safety profile for patients with advanced adrenocortical carcinoma. They also highlighted the potential immunomodulatory effect of cabozantinib, suggesting that it could be used in combination therapy with immunotherapy for these patients.
It is important to note that several authors of the study disclosed ties to pharmaceutical companies, including Exelixis, the manufacturer of cabozantinib, which funded the research.
This study provides valuable insights into the potential efficacy of cabozantinib in treating advanced adrenocortical carcinoma and opens up possibilities for future combination therapies in this patient population.
